<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01541813</url>
  </required_header>
  <id_info>
    <org_study_id>Afssaps 201O-A00866-33</org_study_id>
    <nct_id>NCT01541813</nct_id>
  </id_info>
  <brief_title>Rare Iron Overloads Except C282Y Homozygosity : Description and Characterization.</brief_title>
  <acronym>HEPCIDEF</acronym>
  <official_title>Clinical, Biological, Genetic and Functional Characterization of Rare Iron Overload Phenotypes Associated With Hepcidin Deficiency Except C282Y Homozygosity.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rennes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rennes University Hospital</source>
  <brief_summary>
    <textblock>
      Chronic iron overload is responsible for morbidity and mortality. There are many genetic and
      acquired causes. One of them is an hepcidin deficiency. Hepcidin is the regulating hormone
      for iron. The study explores this specific cause, and aim to characterize this iron overload
      in term of clinical, biological, genetic and functional specificities.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      One of chronic iron overload profiles is a deficit in hepcidin. Hepcidin is the regulating
      hormone for iron. This specific profile is characterized by an elevated serum iron, an
      elevated transferrin saturation, and parenchymal damages of iron overload. This disease is
      not connected with known mutations of iron metabolism genes.

      The main objective of this study is the clinical, biological, genetic and functional
      characterization of rare iron overload phenotypes associated with hepcidin deficiency except
      C282Y homozygosity.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    rare overload and low recruitment
  </why_stopped>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">62</enrollment>
  <condition>Rare Iron Overloads Except C282Y Homozygosity</condition>
  <arm_group>
    <arm_group_label>iron overloads except C282Y homozygosity</arm_group_label>
    <description>Patients with an iron overloads except C282Y homozygosity</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with a rare iron overloads except C282Y homozygosity.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Biological profile suggesting hepcidin deficiency:

               -  high serum iron (&gt; 25μmol / l) checked at least 2 times.

               -  increased transferrin saturation coefficient (&gt; 50 %) checked at least 2 times,
                  and calculated from transferrinemia.

          -  Proved hepatic iron overload: using a dosage of iron hepatic concentration either on
             hepatic biopsy, or by MRI according to the method of iron overload quantification. A
             threshold of 100 µmol / g is set.

          -  Patient's written consent for examination and collection of genetic data to set the
             diagnosis.

        Non inclusion criteria:

          -  HFE hemochromatosis: C282Y/C282Y homozygosity

          -  Treatment by iterative phlebotomies (more than 2 phlebotomies)

          -  Hematological diseases with dyserythropoiesis and/or repeated transfusions

          -  Low haptoglobin level, suggesting chronic hemolysis or myelodysplasia

          -  Long-term iron oral and/or parenteral supplementation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edouard Bardou-Jacquet, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Rennes</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kremlin-Bicêtre Hospital</name>
      <address>
        <city>Kremlin-Bicêtre</city>
        <zip>94270</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU - Huriez Hospital</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Limoges CHU</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lyon Sud Hospital</name>
      <address>
        <city>Lyon</city>
        <zip>69945</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of conception</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Eloi Hospital - CHU</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emilie Muller Hospital</name>
      <address>
        <city>Mulhouse</city>
        <zip>68070</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Center</name>
      <address>
        <city>Mulhouse</city>
        <zip>68070</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BP 86709</name>
      <address>
        <city>Orléans</city>
        <zip>45067</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Purpan CHU</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2012</study_first_submitted>
  <study_first_submitted_qc>February 29, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 1, 2012</study_first_posted>
  <last_update_submitted>March 9, 2015</last_update_submitted>
  <last_update_submitted_qc>March 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rare iron overload</keyword>
  <keyword>hepcidin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iron Overload</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iron</mesh_term>
    <mesh_term>Hepcidins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

